Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-2125 plus ipilimumab versus ipilimumab in anti-PD-1 refractory melanoma
NL-OMON50695Phase 3Completed
- Sponsor
- Aceragen, Inc.
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Ipilimumab alone with IMO-2125 plus ipilimumab (2 arms). Primary endpoints: Objective response rate by blinded independent review and Overall survival. Started Feb 2019; status: completed.
02
Drugs
tilsotolimodipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON50695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50695.